YTEN Stock Overview
Operates as an agricultural bioscience company that focuses on commercializing products using the Camelina oilseeds in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Yield10 Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.50 |
| 52 Week High | US$17.26 |
| 52 Week Low | US$0.35 |
| Beta | 1.43 |
| 11 Month Change | -28.57% |
| 3 Month Change | -65.04% |
| 1 Year Change | -91.51% |
| 33 Year Change | -99.59% |
| 5 Year Change | -99.58% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06M
Aug 10Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?
Nov 12
Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans
Jul 19Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Will Probably Find It Hard To See A Huge Raise This Year
May 18Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Situation
Apr 14Yield10 Bio secures $12.7M capital raise
Feb 01Yield10 Bioscience under pressure on launching stock offering
Jan 29When Will Yield10 Bioscience, Inc. (NASDAQ:YTEN) Become Profitable?
Jan 22
We're Keeping An Eye On Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Rate
Nov 23Yield10 Bioscience, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 13Shareholder Returns
| YTEN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 19.1% | 2.4% | 2.2% |
| 1Y | -91.5% | 16.2% | 31.7% |
Return vs Industry: YTEN underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: YTEN underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| YTEN volatility | |
|---|---|
| YTEN Average Weekly Movement | 37.1% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: YTEN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: YTEN's weekly volatility has increased from 31% to 37% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 29 | Olly Peoples | www.yield10bio.com |
Yield10 Bioscience, Inc. operates as an agricultural bioscience company that focuses on commercializing products using the Camelina oilseeds in the United States. Its products include Camelina oil for production of high levels of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA); and for use as a low-carbon intensity feedstock oil for biofuels, including biodiesel, renewable diesel (RD), and sustainable aviation fuel (SAF). The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017.
Yield10 Bioscience, Inc. Fundamentals Summary
| YTEN fundamental statistics | |
|---|---|
| Market cap | US$363.66k |
| Earnings (TTM) | -US$12.70m |
| Revenue (TTM) | US$750.00k |
0.5x
P/S Ratio0.0x
P/E RatioIs YTEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YTEN income statement (TTM) | |
|---|---|
| Revenue | US$750.00k |
| Cost of Revenue | US$7.21m |
| Gross Profit | -US$6.46m |
| Other Expenses | US$6.25m |
| Earnings | -US$12.70m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -18.34 |
| Gross Margin | -860.93% |
| Net Profit Margin | -1,693.60% |
| Debt/Equity Ratio | -16.0% |
How did YTEN perform over the long term?
See historical performance and comparison